S

Seaport Therapeutics Stock

HealthTech

Looking to sell Seaport Therapeutics stock or options?

Founded: 2024Funding to Date: $330Mhttps://www.seaporttx.com

Seaport Therapeutics is focused on creating new neuropsychiatric medications targeting areas with significant unmet patient needs. Their treatments are designed for oral bioavailability, which avoids first-pass metabolism and minimizes liver toxicity and other adverse effects, thereby improving the quality of life for individuals with neuropsychiatric disorders.

Investors Include:

CPP Investments, Gray's Creek Capital Partners, Foresite Capital, Hawktail, T. Rowe Price Group, Third Rock Ventures, Sofinnova Investments, The Invus Group, Goldman Sachs Asset Management, PureTech Health, ARCH Venture Partners, General Atlantic.

Own Seaport Therapeutics stock or options?

Get an instant valuation

  • Completely free
  • 100% confidential & secure
  • Takes less than a minute
100% private & secure